Multiple responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase inhibitor

被引:15
|
作者
Harper, ME
Goddard, L
Glynne-Jones, E
Assender, J
Dutkowski, CM
Barrow, D
Dewhurst, OL
Wakeling, AE
Nicholson, RI
机构
[1] Cardiff Univ, Welsh Sch Pharm, Tenovus Ctr Canc Res, Cardiff CF10 3XF, S Glam, Wales
[2] Astra Zeneca Pharmaceut, Macclesfield, Cheshire, England
来源
PROSTATE | 2002年 / 52卷 / 01期
关键词
prostate cell lines; tyrosine kinase inhibitor; EGF receptor; MAPK;
D O I
10.1002/pros.10069
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. Epidermal growth factor receptor (EGF-R) autophosphorylation is essential for its intracellular mitogenic signaling via the MAPK pathway and for interaction in other cellular processes. Inhibition of this activity in tumor cells that predominantly utilise EGF-R therefore offers an alternative approach to therapy. METHODS. The ability of a specific inhibitor of EGF-R tyrosine kinase, ZM 252868, (TKI) to alter various parameters related to growth in DU145 and PC3 cell lines was investigated, by immunocytochemistry, Northern blotting, Western blotting and invasion assays. RESULTS. In DU145 cultures, the total cell population and number of cells in cell cycle decreased in the presence of TKI whilst the apoptotic rate was significantly increased. Reduction in autophosphorylation of the EGF-R, membrane expression of EGF-R, activation of the MAPK, p38, and JNK enzymes and the invasive capacity of DU145 cells was observed in the TKI treated cells. Under the same conditions, PC3 cell growth and EGF-R expression and MAPK activation were not affected. The use of inhibitors of intracellular signaling indicated that the DU145 cells, in contrast to PC3 cells, predominantly utilize EGF-R activation of the MAPK signaling pathway for growth. CONCLUSIONS. In prostatic cancer patients, in whom androgen resistance has developed and whose tumors have upregulated EGF-R for growth, specific TKI's may offer an important therapy option. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:59 / 68
页数:10
相关论文
共 50 条
  • [1] Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells
    Spector, Neil L.
    Yarden, Yosef
    Smith, Bradley
    Lyass, Ljuba
    Trusk, Patricia
    Pry, Karen
    Hill, Jason E.
    Xia, Wenle
    Seger, Rony
    Bacus, Sarah S.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (25) : 10607 - 10612
  • [2] Sporostatin, a novel and specific inhibitor of EGF receptor kinase
    Murakami, Y
    Ishii, A
    Mizuno, S
    Yaginuma, S
    Uehara, Y
    ANTICANCER RESEARCH, 1999, 19 (5B) : 4145 - 4149
  • [3] Iressa™.: Oncolytic, EGF receptor tyrosine kinase inhibitor.
    Levin, M
    D'Souza, N
    Castañer, J
    DRUGS OF THE FUTURE, 2002, 27 (04) : 339 - 345
  • [4] Somatic mutations of the EGF receptor and their signal transducers affect the efficacy of EGF receptor-specific tyrosine kinase inhibitors
    Gotoh, Noriko
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2011, 4 (04): : 403 - 409
  • [5] Evaluation of EGF receptor tyrosine kinase inhibitors identifies a potential selective inhibitor of MAP kinase
    Edwards, J
    Gibb, CS
    Robins, D
    Bartlett, JMS
    BRITISH JOURNAL OF CANCER, 1998, 78 (02) : 151 - 152
  • [6] Role of EGF receptor tyrosine kinase activity in antiapoptotic effect of EGF on mouse hepatocytes
    Musallam, L
    Éthier, C
    Haddad, PS
    Bilodeau, M
    AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2001, 280 (06): : G1360 - G1369
  • [7] AGING - INCREASED ACTIVATION OF EGF-RECEPTOR (EGF-R) TYROSINE KINASE IN COLONIC MUCOSAL MEMBRANE BY EGF AND TGF-ALPHA
    RELAN, NK
    MAJUMDAR, APN
    GASTROENTEROLOGY, 1993, 104 (04) : A642 - A642
  • [8] Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ('Iressa')
    Sewell, JM
    Macleod, KG
    Ritchie, A
    Smyth, JF
    Langdon, SP
    BRITISH JOURNAL OF CANCER, 2002, 86 (03) : 456 - 462
  • [9] TGF-α-driven tumor growth is inhibited by an EGF receptor tyrosine kinase inhibitor
    El-Obeid, A
    Hesselager, G
    Westermark, B
    Nistér, M
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 290 (01) : 349 - 358
  • [10] Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 (‘Iressa’)
    J M Sewell
    K G Macleod
    A Ritchie
    J F Smyth
    S P Langdon
    British Journal of Cancer, 2002, 86 : 456 - 462